Patents by Inventor Ernst Lengyel

Ernst Lengyel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCERS WITH CT45 TARGETED THERAPIES
    Publication number: 20220153797
    Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 19, 2022
    Applicants: The University of Chicago, Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V.
    Inventors: Ernst Lengyel, Matthias Mann, Marion Curtis, Fabian Coscia
  • Methods of treating cancers with CT45 targeted therapies
    Patent number: 11261223
    Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: March 1, 2022
    Assignees: The University of Chicago, Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.
    Inventors: Ernst Lengyel, Matthias Mann, Marion Curtis, Fabian Coscia
  • METHODS OF TREATING CANCERS WITH CT45 TARGETED THERAPIES
    Publication number: 20190144516
    Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
    Type: Application
    Filed: May 11, 2017
    Publication date: May 16, 2019
    Inventors: Ernst Lengyel, Matthias Mann, Marion Curtis, Fabian Coscia
  • Receptor-mediated delivery: compositions and methods
    Patent number: 9127293
    Abstract: Compositions and methods for delivering an agent to a cell comprising a prolactin receptor are provided. Also provided is a method of inhibiting a breast, ovarian or prostate cancer cell, where the method includes a step of contacting the cell with a complex comprising a prolactin receptor ligand linked to at least one of an RNAi-inducing agent, a polynucleotide sequence encoding a polypeptide, an miRNA, a cytotoxic moiety, a chemotherapeutic moiety, a radioactive moiety or a nanoparticle. Methods of detecting a cancer cell expressing a prolactin receptor are also provided.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: September 8, 2015
    Assignee: The University of Chicago
    Inventors: Ernst Lengyel, Anthony Kossiakoff, Joseph Piccirilli
  • Compositions and Methods for Treating and/or Preventing Cancer by Inhibiting Fatty Acid Binding Proteins
    Publication number: 20140363522
    Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
    Type: Application
    Filed: May 13, 2014
    Publication date: December 11, 2014
    Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
  • Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
    Patent number: 8748470
    Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: June 10, 2014
    Assignee: The University of Chicago
    Inventors: Ernst Lengyel, Kristin Nieman, Hilary Kenny
  • COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS
    Publication number: 20120289570
    Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
    Type: Application
    Filed: March 16, 2012
    Publication date: November 15, 2012
    Inventors: Ernst Lengyel, Kristin Nieman, Hilary Kenny
  • RECEPTOR-MEDIATED DELIVERY: COMPOSITIONS AND METHODS
    Publication number: 20090317855
    Abstract: Compositions and methods for delivering an agent to a cell comprising a prolactin receptor are provided. Also provided is a method of inhibiting a breast, ovarian or prostate cancer cell, where the method includes a step of contacting the cell with a complex comprising a prolactin receptor ligand linked to at least one of an RNAi-inducing agent, a polynucleotide sequence encoding a polypeptide, an miRNA, a cytotoxic moiety, a chemotherapeutic moiety, a radioactive moiety or a nanoparticle. Methods of detecting a cancer cell expressing a prolactin receptor are also provided.
    Type: Application
    Filed: July 26, 2007
    Publication date: December 24, 2009
    Inventors: Ernst Lengyel, Anthony Kossiakoff, Joseph Piccirilli